Loading clinical trials...

AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 4NCT01012869

AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study

Chronically total occlusions (CTO) are difficult to treat and have high risk for restenosis. Although everolimus-eluting stents (EES) \[(Xience, Abbott Vascular) or Promus (Boston Scientific)\] are ve...

Lead sponsor: North Texas Veterans Healthcare System•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

COMPLETEDPhase 3

ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial

NCT00378612 · Coronary Occlusions

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 29, 2013Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment100

Start dateNov 2009

Last updatedOct 29, 2013

Condition

Coronary Occlusions

Locations shown

Dallas VA Medical Center

Dallas, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2013Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions